Bicycle Therapeutics Reports Q3 Earnings Beat with Significant Revenue Growth
Bicycle Therapeutics (BCYC) reported third-quarter financial results that significantly exceeded market expectations. The company posted a GAAP EPS of -$0.15, beating estimates by $0.33, and reported revenue of $34.06 million, which represents a 190.4% increase year-over-year and surpassed consensus estimates by $21.86 million. Despite the strong financial beat, the company is undergoing strategic shifts, including the deprioritization of Zelenectide in favor of targeting EphA2+ tumors. Analysts at Oppenheimer have upgraded the stock to 'Outperform,' citing confidence in the company's platform for cancer treatment.
Tickers: $BCYC